The overall objective of this study was to assess whether MMP-9 serum levels increases over time in DMD patients and to provide proof that it could be used as exploratory biomarker in clinical trials aiming to restore dystrophin. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.